Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt; Kim A Papp; Christopher E M Griffiths; Luis Puig; Jamie Weisman; Yves Dutronc; Lisa Farmer Kerr; Dapo Ilo; Lotus Mallbris; Matthias Augustin

doi:10.1007/s40257-018-0353-x

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt.

Original language	English
Pages (from-to)	457
Journal	American journal of clinical dermatology
Volume	19
Issue number	3
Early online date	29 Mar 2018
DOIs	https://doi.org/10.1007/s40257-018-0353-x
Publication status	Published - Jun 2018

Access to Document

10.1007/s40257-018-0353-x

Fingerprint

Dive into the research topics of 'Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)'. Together they form a unique fingerprint.

Cite this

Blauvelt, A., Papp, K. A., Griffiths, C. E. M., Puig, L., Weisman, J., Dutronc, Y., Kerr, L. F., Ilo, D., Mallbris, L., & Augustin, M. (2018). Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). American journal of clinical dermatology, 19(3), 457. https://doi.org/10.1007/s40257-018-0353-x

@article{85549e33b39046d6b2bcdb40be3b6c89,

title = "Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)",

abstract = "The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt.",

author = "Andrew Blauvelt and Papp, {Kim A} and Griffiths, {Christopher E M} and Luis Puig and Jamie Weisman and Yves Dutronc and Kerr, {Lisa Farmer} and Dapo Ilo and Lotus Mallbris and Matthias Augustin",

year = "2018",

month = jun,

doi = "10.1007/s40257-018-0353-x",

language = "English",

volume = "19",

pages = "457",

journal = "American journal of clinical dermatology",

issn = "1175-0561",

publisher = "Adis International Ltd",

number = "3",

}

Blauvelt, A, Papp, KA, Griffiths, CEM, Puig, L, Weisman, J, Dutronc, Y, Kerr, LF, Ilo, D, Mallbris, L & Augustin, M 2018, 'Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)', American journal of clinical dermatology, vol. 19, no. 3, pp. 457. https://doi.org/10.1007/s40257-018-0353-x

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). / Blauvelt, Andrew; Papp, Kim A; Griffiths, Christopher E M et al.
In: American journal of clinical dermatology, Vol. 19, No. 3, 06.2018, p. 457.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Correction to

T2 - Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

AU - Blauvelt, Andrew

AU - Papp, Kim A

AU - Griffiths, Christopher E M

AU - Puig, Luis

AU - Weisman, Jamie

AU - Dutronc, Yves

AU - Kerr, Lisa Farmer

AU - Ilo, Dapo

AU - Mallbris, Lotus

AU - Augustin, Matthias

PY - 2018/6

Y1 - 2018/6

N2 - The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt.

AB - The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt.

U2 - 10.1007/s40257-018-0353-x

DO - 10.1007/s40257-018-0353-x

M3 - Article

C2 - 29600394

SN - 1175-0561

VL - 19

SP - 457

JO - American journal of clinical dermatology

JF - American journal of clinical dermatology

IS - 3

ER -

Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y et al. Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). American journal of clinical dermatology. 2018 Jun;19(3):457. Epub 2018 Mar 29. doi: 10.1007/s40257-018-0353-x